Il12rb2

C57BL/6 were purchased from Janvier (Saint Berthevin, France). Il12rb2^−/−, Il12a^−/−, Ebi3^−/−, Ifng^−/− and Il23a^−/− were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and Regeneron (Tarrytown, NY, USA), respectively. Il12b^−/− mice were purchased from Jackson Laboratory or provided by E. von Stebut and K. Schwonberg (Mainz, Germany). Vd1^−/− animals were provided by K. Kishihara (Nagasaki, Japan). Mice were kept in house under specific pathogen-free conditions. Animal experiments were approved by the Swiss Cantonal Veterinary Office (33/2010 and 68/2013).

CD45.1, 2D2, Tbx21^-/-, Il12rb2^-/- and Rag1^-/- mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). 2D2/Tbx21^-/- mice were generated by crossing 2D2 mice with Tbx21^-/- mice and used for adoptive EAE experiments. All experimental procedures were performed with the approval of the Institutional Animal Care and Use Committee of Thomas Jefferson University.
To study the role of Il12rb2^-/- in ThGM development, total CD4⁺ T cells from WT and Il12rb2^-/- mice were purified using a CD4 isolation kit (Miltenyi Biotec). Three days before immunization, 1x10⁷ CD4⁺ T cells from WT and Il12rb2^-/- mice at a 1:1 ratio were transferred to Rag1^-/- recipient mice. Rag1^-/- mice were immunized by subcutaneous injection of 200 μg MOG_35-55 (Genscript, CA, USA) in CFA. Mice received 200 ng of pertussis toxin (Sigma-Aldrich) on days 0 and 2 p.i. and were scored daily for clinical signs as follows: 0, no sign of clinical disease; 1, paresis of the tail; 2, paresis of one hind limb; 3, paresis of both hind limbs; 4, paresis of the abdomen; 5, moribund/death.